Weight loss effects vary by indication, with approximately 1522% body weight reduction observed in obesity trials (SURMOUNT-1), while more modest reductions are typically seen in diabetes patients
We then hypothesized that the inefficacy of the peptide in inducing cell death in both types of cells might be attributed to inadequate cellular uptake
The Bottom Line Orforglipron (Foundayo) is not simply "Ozempic in pill form." It represents a different molecular strategy for activating the GLP-1 receptor, and that difference may significantly expand access for people who are unwilling or unable to use injectable medications
How does the PlexusDx Precision Peptide Genetic Test help personalize my treatment
This is a preview of subscription content, access via your institution Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription 27,99 / 30 days cancel any time Subscribe to this journal Receive 12 print issues and online access 186,36 per year only 15,53 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF
